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Abstract	  
Human	  hepatic	  flavin-­‐containing	  monooxygenase	  3	  is	  a	  phase	  I	  drug-­‐metabolizing	  enzyme	  
that	  is	  responsible	  for	  the	  oxidation	  of	  a	  variety	  of	  drugs	  and	  xenobiotics.	  This	  work	  reports	  
on	  a	  high-­‐throughput	  rapid	  colorimetric	  assay	  for	  the	  screening	  of	  substrates	  or	  inhibitors	  of	  
this	  enzyme.	  The	  method	  is	  based	  on	  the	  competition	  of	  two	  substrates	  for	  access	  to	  the	  
active	  site	  of	  hFMO3	  whereby	  the	  enzymatic	  product	  of	  the	  first	  drug	  converts	  nitro-­‐5-­‐
thiobenzoate	  (TNB,	  yellow)	  to	  5,5’-­‐dithiobis(2-­‐nitrobenzoate)	  (DTNB,	  colourless).	  Upon	  
addition	  of	  a	  competing	  substrate,	  the	  amount	  of	  detected	  DNTB	  is	  decreased.	  The	  assay	  is	  
validated	  testing	  three	  known	  substrates	  of	  hFMO3,	  namely	  benzydamine,	  tozasertib	  and	  
tamoxifen.	  The	  latter	  drugs	  resulted	  in	  41%	  -­‐	  55%	  inhibition.	  In	  addition,	  two	  other	  drugs	  
also	  classified	  as	  doping	  drugs,	  selegiline	  and	  clomiphene,	  were	  selected	  based	  on	  their	  
chemical	  structure	  similarity	  to	  known	  substrates	  of	  hFMO3.	  These	  drugs	  showed	  21%	  and	  
60%	  inhibition	  in	  the	  colorimetric	  assay	  and	  therefore	  were	  proven	  to	  be	  hFMO3	  substrates.	  
LC-­‐MS	  was	  used	  to	  confirm	  their	  N-­‐oxide	  products.	  Further	  characterisation	  of	  these	  newly	  
identified	  hFMO3	  substrates	  was	  performed	  determining	  their	  Km	  and	  kcat	  values	  that	  
resulted	  to	  be	  314	  µM	  and	  1.4	  min-­‐1	  for	  selegiline	  and,	  18	  µM	  and	  0.1	  min-­‐1	  for	  clomiphene.	  
This	  method	  paves	  the	  way	  for	  a	  rapid	  automated	  high	  throughput	  screening	  of	  nitrogen-­‐
containing	  compounds	  as	  substrates/inhibitors	  of	  hFMO3.	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1.   INTRODUCTION 
Human	  flavin-­‐containing	  monooxygenase	  3	  (hFMO3)	  is	  a	  phase	  I	  drug-­‐metabolizing	  enzyme	  
predominantly	  expressed	  in	  the	  liver	  where	  its	  substrates,	  generally	  nitrogen-­‐,	  sulfur-­‐	  and	  
phosphorous-­‐containing	  soft	  nucleophiles	  are	  transformed	  into	  more	  polar	  and	  excretable	  
metabolites	  [1-­‐3].	  Unlike	  cytochromes	  P450	  (the	  most	  important	  phase	  I	  drug	  metabolizing	  
enzymes),	  hFMO3	  produces	  few	  toxic	  metabolites	  and	  therefore	  designing	  drugs	  that	  are	  
metabolized	  by	  hFMO3	  rather	  than	  by	  cytochromes	  P450	  may	  lead	  to	  significant	  clinical	  
advantages	  [4].	  In	  addition,	  hFMO3	  is	  not	  readily	  induced	  or	  inhibited,	  like	  cytochromes	  
P450,	  consequently	  minimizing	  potential	  adverse	  drug-­‐drug	  interactions	  [4,	  5].	  However,	  
designing	  such	  drugs	  requires	  a	  rapid	  selection	  method	  which	  according	  to	  our	  knowledge	  
does	  not	  currently	  exist	  although	  our	  group	  has	  previously	  described	  an	  electrochemically	  
based	  assay	  for	  hFMO3	  [6].	  	  
In	  order	  to	  develop	  a	  high-­‐throughput	  colorimetric	  detection	  method	  for	  hFMO3	  substrates	  
or	  inhibitors,	  methimazole-­‐dependent	  TNB	  (nitro-­‐5-­‐thiobenzoate)	  oxidation	  assay	  was	  
chosen	  as	  the	  starting	  point.	  Methimazole	  is	  a	  known	  substrate	  of	  hFMO3	  that	  is	  S-­‐
oxygenated	  by	  the	  enzyme	  and	  it	  has	  been	  widely	  employed	  in	  the	  past	  for	  FMO	  activity	  
measurement	  using	  a	  colorimetric	  assay	  developed	  by	  Dixit	  and	  Roche	  [7].	  The	  main	  
advantages	  of	  this	  assay	  are:	  (a)	  the	  specificity	  of	  methimazole	  S-­‐oxide	  (product	  of	  hFMO3	  
enzyme	  activity)	  for	  TNB	  and	  (b)	  its	  colorimetric	  nature	  leading	  to	  possible	  conversion	  into	  a	  
high	  throughput	  screening	  assay.	  
Herein	  we	  describe	  a	  competitive	  assay	  based	  on	  the	  concept	  that	  adding	  a	  second	  N-­‐
containing	  substrate	  or	  inhibitor	  to	  the	  reaction	  mixture,	  the	  molecule	  would	  compete	  with	  
methimazole	  for	  the	  enzyme	  activity.	  As	  a	  result,	  a	  lower	  amount	  of	  methimazole	  is	  
converted	  into	  methimazole	  S-­‐oxide	  and	  this	  can	  be	  measured	  by	  the	  differences	  in	  
absorbance.	  Since	  the	  Dixit	  and	  Roche	  assay	  is	  based	  on	  the	  re-­‐oxidation	  of	  TNB	  to	  DTNB	  
the	  formation	  of	  a	  disulfide	  conjugate	  between	  methimazole	  S-­‐oxide	  and	  TNB	  is	  crucial	  and	  
therefore	  only	  N-­‐containing	  substrates	  that	  are	  converted	  by	  hFMO3	  into	  N-­‐oxide	  products	  
can	  be	  tested	  as	  competitive	  substrates.	  A	  scheme	  of	  the	  different	  steps	  of	  the	  colorimetric	  
assay	  are	  shown	  in	  Figure	  1.	  	  
Initially,	  to	  prove	  that	  the	  assay	  is	  indeed	  reliable	  in	  determining	  whether	  a	  chemical	  
compound	  is	  a	  substrate	  of	  hFMO3,	  three	  known	  substrates	  namely	  benzydamine	  (anti-­‐
inflammatory	  drug),	  tamoxifen	  (anti-­‐breast	  cancer)	  and	  tozasertib	  (kinase	  inhibitor	  used	  in	  
cancer	  treatment)	  were	  selected.	  All	  these	  drugs	  have	  been	  shown	  to	  be	  converted	  to	  their	  
N-­‐oxide	  product	  by	  the	  action	  of	  purified	  hFMO3	  [8-­‐10].	  
Subsequently,	  the	  colorimetric	  assay	  was	  also	  exploited	  for	  the	  identification	  of	  putative	  
new	  substrates	  of	  hFMO3.	  Two	  doping	  drugs,	  clomiphene	  and	  selegiline,	  were	  tested	  with	  
the	  colorimetric	  assay	  and	  after	  a	  positive	  result,	  their	  corresponding	  N-­‐oxide	  products	  were	  
identified	  by	  LC-­‐MS	  and	  finally	  their	  kinetic	  parameters	  including	  Km	  and	  kcat	  measured.	  
	  
2.   MATERIALS AND METHODS 
2.1.	  Materials	  
Methimazole	  (N-­‐methyl-­‐2-­‐mercaptoimidazole),	  benzydamine	  (3-­‐(1-­‐benzyl-­‐1H-­‐indazol-­‐3-­‐
yloxy)-­‐N,N-­‐dimethylpropan-­‐1-­‐amine),	  tamoxifen	  ((Z)-­‐2-­‐[4-­‐(1,2-­‐diphenylbut-­‐1-­‐enyl)phenoxy]-­‐
N,N-­‐dimethylethanamine),	  methanol,	  ethanol,	  NADPH,	  DL-­‐dithiothreitol	  (DTT)	  and	  5,5’-­‐
dithiobis(2-­‐nitrobenzoate)	  (DTNB)	  and	  salts	  were	  purchased	  from	  Sigma–Aldrich	  (Italy).	  
Tozasertib	  (N-­‐[4-­‐[4-­‐(4-­‐methylpiperazin-­‐1-­‐yl)-­‐6-­‐[(5-­‐methyl-­‐1H-­‐pyrazol-­‐3-­‐
yl)amino]pyrimidin2yl]sulfanylphenyl]cyclopropane	  
carboxamide)	  was	  purchased	  from	  Aurogene	  (Italy).	  Clomiphene	  (2-­‐[4-­‐(2-­‐chloro-­‐1,2-­‐
diphenylethenyl]phenoxy]-­‐N,N-­‐diethylethanamine),	  selegiline	  ((2R)-­‐N-­‐methyl-­‐1-­‐phenyl-­‐N-­‐
prop-­‐2-­‐ynylpropan-­‐2-­‐amine),	  clomiphene	  N-­‐oxide	  and	  selegiline	  N-­‐oxide	  were	  purchased	  
from	  DBA	  Italia	  (Italy).	  	  
	  
2.2. Protein Expression and Purification 
All	  steps	  were	  of	  expression	  and	  purification	  were	  performed	  according	  to	  previously	  
published	  protocols	  [8,9].	  Wild	  type	  hFMO3	  was	  expressed	  in	  E.	  coli	  JM109	  cells	  and	  grown	  
24	  h	  post-­‐induction.	  The	  protein	  was	  purified	  via	  Ni	  affinity	  chromatography.	  Spectra	  of	  the	  
eluted	  fractions	  (with	  40	  mM	  histidine)	  were	  recorded	  using	  a	  diode	  array	  HP-­‐8453E	  
spectrophotometer.	  FAD	  containing	  fractions	  with	  the	  characteristic	  absorption	  peaks	  at	  
375	  and	  442	  nm	  were	  pooled	  and	  exchanged	  to	  storage	  buffer	  (100	  mM	  potassium	  
phosphate	  buffer	  pH	  7.4,	  20%	  glycerol	  and	  1	  mM	  EDTA)	  by	  30	  kDa	  cutoff	  Amicon	  
membranes	  and	  stored	  at	  -­‐20°C.	  
	  
2.3. Methimazole assay 
Methimazole-­‐dependent	  TNB	  oxidation	  assay	  was	  previously	  described	  by	  Dixit	  and	  Roche	  
as	  a	  method	  to	  determine	  catalytic	  activities	  of	  flavin-­‐containing	  monooxygenases	  through	  
spectrophotometrical	  measurement	  [7].	  Each	  reaction	  was	  performed	  at	  37°C	  using	  0.84	  
µM	  hFMO3	  in	  presence	  of	  1	  mM	  NADPH	  and	  1	  mM	  methimazole	  in	  30	  mM	  Tris-­‐HCl	  pH	  8.0.	  	  
DTNB	  (60	  µM)	  which	  is	  colourless,	  is	  initially	  reduced	  by	  30	  µM	  dithiothreitol	  (DTT)	  to	  5-­‐
thionitrobenzoate	  (TNB)	  upon	  incubation	  for	  5	  minutes	  at	  37°C.	  TNB	  has	  a	  maximum	  
absorbance	  at	  412	  nm.	  Methimazole	  itself	  cannot	  not	  react	  with	  TNB	  but	  when	  it	  is	  
converted	  by	  hFMO3	  to	  its	  oxidised	  product	  (methimazole	  S-­‐oxide),	  the	  latter	  forms	  a	  
disulfide	  conjugate	  with	  TNB	  which	  is	  re-­‐oxidised	  to	  DTNB.	  	  
	  
2.4. Colorimetric competition assay  
Benzydamine	  hydrochloride	  was	  dissolved	  both	  in	  30	  mM	  Tris-­‐HCl	  buffer	  (pH	  8.0)	  and	  
ethanol.	  The	  ability	  of	  benzydamine	  to	  compete	  with	  methimazole	  for	  hFMO3	  activity	  was	  
evaluated	  at	  different	  concentrations,	  in	  the	  range	  of	  0	  to	  1	  mM.	  The	  reactions	  were	  
performed	  as	  described	  above	  for	  the	  methimazole	  assay,	  but	  with	  the	  addition	  of	  
benzydamine	  in	  the	  reaction	  mixture.	  The	  non-­‐enzymatic	  reaction	  was	  performed	  in	  the	  
absence	  of	  enzyme	  and	  in	  presence	  of	  1	  mM	  benzydamine.	  The	  same	  reactions	  were	  also	  
performed	  in	  ethanol	  (2.5%	  final	  concentration).	  Ethanol	  was	  used	  to	  test	  the	  assay	  
feasibility	  also	  in	  the	  presence	  of	  an	  organic	  solvent.	  	  The	  percentage	  of	  inhibition	  was	  
calculated	  by	  subtracting	  the	  amount	  of	  oxidized	  TNB	  at	  1	  min	  from	  the	  amount	  oxidized	  
after	  31	  minutes.	  As	  a	  negative	  control	  a	  drug	  known	  to	  be	  a	  substrate	  of	  cytochrome	  P450,	  
ketamine	  ((RS)-­‐2-­‐(2-­‐Chlorophenyl)-­‐2-­‐(methylamino)cyclohexanone),	  was	  also	  tested	  with	  
the	  colorimetric	  assay.	  As	  expected	  for	  a	  non-­‐substrate,	  no	  differences	  in	  absorbance	  were	  
observed.	  
The	  second	  known	  substrate,	  tamoxifen,	  was	  dissolved	  in	  ethanol.	  The	  ability	  of	  tamoxifen	  
to	  compete	  with	  methimazole	  for	  hFMO3	  activity	  was	  evaluated	  at	  different	  concentrations,	  
in	  the	  range	  0	  to	  100	  µM.	  The	  third	  known	  substrate,	  tozasertib,	  was	  dissolved	  in	  methanol	  
and	  evaluated	  in	  the	  concentration	  range	  0	  to	  200	  µM.	  The	  reaction	  in	  absence	  of	  tozasertib	  
was	  performed	  replacing	  its	  volume	  with	  methanol	  (4%	  final	  concentration,	  which	  was	  
equivalent	  to	  the	  highest	  concentration	  of	  methanol	  used	  in	  the	  reactions).	  The	  non-­‐
enzymatic	  reaction	  was	  performed	  in	  the	  absence	  of	  hFMO3	  and	  in	  presence	  of	  200	  µM	  
tozasertib.	  	  
Selegiline	  was	  dissolved	  in	  30	  mM	  Tris-­‐HCl	  buffer	  (pH	  8.0)	  and	  tested	  in	  the	  concentration	  
range	  from	  0	  to	  1	  mM.	  The	  non-­‐enzymatic	  reaction	  was	  performed	  in	  the	  absence	  of	  the	  
enzyme	  but	  in	  presence	  of	  1	  mM	  selegiline.	  The	  last	  drug	  to	  be	  tested,	  clomiphene	  (0	  to	  50	  
µM),	  was	  dissolved	  in	  methanol.	  The	  control	  reaction	  in	  the	  absence	  of	  this	  drug	  was	  
performed	  replacing	  its	  volume	  with	  methanol	  (1%	  final	  concentration,	  which	  was	  
equivalent	  to	  the	  highest	  concentration	  of	  methanol	  used	  in	  the	  reactions).	  The	  non-­‐
enzymatic	  reaction	  was	  performed	  in	  absence	  of	  hFMO3	  and	  in	  presence	  of	  50	  µM	  
clomiphene.	  
	  
2.5. LC-MS Analyses of selegiline, clomiphene and their corresponding metabolites 
HPLC	  analysis	  was	  performed	  on	  a	  C18	  column	  (Phenomenex	  Luna,	  150	  ×	  2.0	  mm,	  3	  μm	  
particle	  size,	  Phenomenex,	  Torrance,	  CA,	  USA)	  applying	  a	  gradient	  of	  mobile	  phase	  
composition	  based	  on	  an	  aqueous	  0.05%	  formic	  acid	  (solvent	  A)	  and	  acetonitrile	  (solvent	  B).	  
The	  initial	  A:B	  ratio	  of	  5:95	  was	  linearly	  brought	  to	  100:0	  in	  20	  min.	  The	  injection	  volume	  
was	  20	  μL	  and	  the	  flow	  rate	  0.2	  mL	  min-­‐1.	  A	  LTQ	  Orbitrap	  hybrid	  mass	  spectrometer	  
(Thermo	  Scientific,	  Bremen,	  Germany),	  equipped	  with	  a	  ESI	  ion	  source,	  was	  as	  high	  resolving	  
power	  MS	  analyzer.	  The	  syringe	  pump	  effluent	  was	  delivered	  to	  the	  ion	  source	  at	  10	  
µL/min,	  using	  nitrogen	  as	  both	  sheath	  and	  auxiliary	  gas.	  The	  source	  voltage	  was	  set	  to	  4.5	  
kV.	  The	  heated	  capillary	  temperature	  was	  maintained	  at	  260°C.	  The	  acquisition	  method	  
used	  had	  previously	  been	  optimized	  in	  the	  tuning	  sections	  for	  the	  parent	  compound	  
(capillary,	  magnetic	  lenses	  and	  collimating	  octapoles	  voltages)	  in	  order	  to	  achieve	  maximum	  
sensitivity.	  The	  main	  tuning	  parameters	  adopted	  for	  the	  ESI	  source	  were	  19	  V	  for	  capillary	  
voltage	  and	  50	  V	  for	  tube	  lens.	  Full	  scan	  spectra	  were	  acquired	  in	  the	  range	  100-­‐500	  m/z.	  
MSn	  spectra	  were	  acquired	  in	  the	  range	  between	  ion	  trap	  cut-­‐off	  and	  precursor	  ion	  m/z	  
values.	  Mass	  resolution	  was	  set	  to	  30000.	  Mass	  accuracy	  of	  recorded	  ions	  (vs.	  calculated)	  
was	  ±	  0.001	  u	  (without	  internal	  calibration).	  Spectra	  were	  acquired	  in	  the	  positive	  HRMS	  
and	  MS/MS	  mode,	  with	  a	  precursor	  ion	  normalized	  collision	  energy	  of	  25%.	  
	  
2.6. Enzyme-substrate incubations and HPLC analysis 
For	  the	  N-­‐oxygenation	  of	  selegiline	  a	  typical	  incubation	  mixture	  consisted	  of	  50	  mM	  
potassium	  phosphate	  buffer	  (pH	  7.4),	  1	  mM	  NADPH,	  different	  concentrations	  of	  the	  
substrate	  and	  0.64	  µM	  of	  purified	  enzyme	  in	  a	  final	  volume	  of	  0.10	  ml.	  Incubations	  were	  
carried	  out	  at	  37°C	  for	  30	  min:	  the	  linearity	  of	  product	  formation	  was	  confirmed	  with	  
purified	  hFMO3	  preparations	  for	  60	  min.	  The	  incubation	  was	  terminated	  by	  the	  addition	  of	  
0.05	  ml	  of	  ice-­‐cold	  methanol.	  The	  aqueous	  supernatant	  was	  centrifuged	  at	  14000	  rpm	  for	  10	  
min	  and	  was	  subjected	  to	  HPLC	  equipped	  with	  an	  analytical	  Zorbax	  Eclipse	  reverse	  phase	  
C18	  column	  (4.6	  x	  150	  mm,	  5	  µm).	  A	  50	  µl	  sample	  was	  injected	  and	  the	  separation	  was	  
performed	  using	  a	  mobile	  phase	  of	  80%	  30	  mM	  potassium	  phosphate	  buffer	  pH	  7.2	  and	  20%	  
of	  acetonitrile	  at	  a	  flow	  rate	  of	  1.0	  ml/min.	  After	  6	  minutes	  a	  linear	  gradient	  was	  applied	  
increasing	  the	  acetonitrile	  to	  50%	  after	  10	  minutes.	  The	  presence	  of	  selegiline	  N-­‐oxide	  was	  
monitored	  at	  the	  210	  nm.	  	  
For	  the	  N-­‐oxygenation	  of	  clomiphene	  the	  same	  conditions	  described	  above	  for	  selegiline	  
were	  followed.	  Incubations	  were	  carried	  out	  at	  37°C	  for	  30	  min	  and	  the	  linearity	  of	  product	  
formation	  was	  confirmed	  with	  purified	  hFMO3	  preparations	  for	  60	  min.	  The	  incubation	  was	  
terminated	  by	  the	  addition	  of	  0.05	  ml	  of	  ice-­‐cold	  methanol.	  Again	  in	  this	  case,	  the	  aqueous	  
supernatant	  was	  centrifuged	  at	  14000	  rpm	  for	  10	  min	  and	  subsequently	  analysed	  by	  HPLC	  
equipped	  with	  an	  analytical	  C18	  column	  (4.6	  x	  150	  mm,	  5	  µm).	  A	  50	  µl	  sample	  was	  injected	  
and	  the	  separation	  was	  performed	  using	  a	  mobile	  phase	  of	  78%	  methanol	  and	  22%	  of	  1%	  
triethylamine	  at	  a	  flow	  rate	  of	  1.0	  ml/min.	  Clomiphene	  N-­‐oxide	  elution	  was	  monitored	  at	  
254	  nm.	  
	  
3.	  RESULTS	  and	  DISCUSSION	  
3.1.	  Colorimetric	  assay	  applied	  to	  known	  substrates	  of	  hFMO3	  
As	  a	  proof	  of	  principle	  that	  the	  colorimetric	  assay	  previously	  described	  by	  Dixit	  and	  Roche	  
[7]	  can	  also	  work	  as	  a	  competitive	  assay	  for	  N-­‐containing	  substrates	  of	  hFMO3,	  several	  
known	  substrates	  of	  the	  enzyme	  were	  tested.	  According	  to	  the	  scheme	  in	  Figure	  1,	  any	  drug	  
that	  can	  compete	  with	  methimazole	  for	  binding	  to	  the	  active	  site	  of	  hFMO3,	  can	  result	  in	  a	  
decrease	  in	  methimazole	  S-­‐oxide	  formed	  which	  will	  subsequently	  effect	  the	  amount	  of	  TNB	  
spectrophotometrically	  detected	  at	  412	  nm.	  	  Human	  FMO3	  can	  act	  on	  heteroatom	  
containing	  substrates	  including	  sulfur	  or	  nitrogen	  but	  for	  the	  competitive	  colorimetric	  assay	  
described	  here,	  only	  N-­‐containing	  substrates	  can	  be	  used	  since	  they	  do	  not	  interfere	  with	  
the	  TNB	  oxidation.	  
The	  first	  substrate	  of	  hFMO3	  to	  be	  investigated	  was	  benzydamine	  [11-­‐13],	  a	  locally-­‐acting	  
nonsteroidal	  anti-­‐inflammatory	  drug	  with	  anaesthetic	  and	  analgesic	  properties	  for	  pain	  
relief	  and	  treatment	  of	  inflammatory	  conditions	  of	  the	  mouth	  and	  throat.	  The	  kinetics	  of	  the	  
competition	  assay	  was	  followed	  for	  30	  minutes	  or	  60	  minutes	  to	  assess	  whether	  longer	  
exposure	  to	  both	  substrates	  could	  affect	  methimazole	  S-­‐oxidation.	  The	  experiments	  were	  
carried	  out	  with	  increasing	  concentrations	  of	  benzydamine	  (0	  to	  1	  mM).	  The	  absorbance	  
values	  measured	  at	  412	  nm	  after	  30	  and	  60	  minutes	  were	  used	  to	  evaluate	  the	  percentage	  
of	  inhibition	  of	  methimazole	  S-­‐oxide	  formation	  due	  to	  the	  presence	  of	  benzydamine.	  The	  
non-­‐enzymatic	  reaction	  was	  used	  as	  the	  100%	  inhibition	  reference	  point	  and	  the	  reaction	  in	  
the	  absence	  of	  benzydamine	  was	  utilized	  as	  the	  0%	  inhibition	  point.	  In	  the	  presence	  of	  
increasing	  concentrations	  of	  benzydamine,	  the	  S-­‐oxygenation	  rates	  decreased.	  
Furthermore,	  since	  the	  molar	  extinction	  coefficient	  of	  DTNB	  is	  known	  (13,800	  M-­‐1	  cm-­‐1	  at	  
412	  nm),	  the	  delta	  absorbance	  measured	  for	  each	  sample	  was	  used	  to	  calculate	  the	  moles	  
of	  TNB	  oxidised	  to	  DTNB,	  which	  were	  equivalent	  to	  the	  moles	  of	  methimazole	  converted	  to	  
the	  S-­‐oxide	  product	  by	  the	  hFMO3	  enzyme.	  As	  expected,	  the	  moles	  of	  methimazole	  which	  
were	  converted	  to	  S-­‐oxide	  product	  decreased	  as	  a	  function	  of	  benzydamine	  concentration.	  
After	  30	  minutes	  and	  in	  the	  presence	  of	  1	  mM	  benzydamine,	  methimazole	  S-­‐oxide	  
formation	  was	  decreased	  to	  47%	  (versus	  ∼45%	  after	  60	  minutes)	  (Figure	  2).	  Since	  inhibition	  
percentages	  were	  found	  to	  be	  comparable	  for	  30	  min	  or	  60	  min	  reactions,	  subsequent	  
experiments	  were	  carried	  out	  for	  the	  shorter	  time	  scale	  of	  30	  min	  without	  further	  
incubation.	  	  
Most	  drugs	  are	  hydrophobic	  and	  therefore	  not	  easily	  dissolved	  in	  aqueous	  buffers,	  so	  the	  
above	  experiments	  were	  repeated	  dissolving	  benzydamine	  in	  ethanol,	  to	  evaluate	  a	  possible	  
extension	  of	  the	  competition	  assay	  to	  more	  hydrophobic	  molecules.	  In	  this	  case	  a	  49%	  
decrease	  in	  methimazole	  conversion	  was	  observed,	  which	  is	  comparable	  to	  values	  obtained	  
with	  benzydamine	  dissolved	  in	  buffer,	  i.e.	  47%.	  Therefore,	  the	  colorimetric	  competition	  
assay	  can	  be	  extended	  to	  less	  soluble	  drugs.	  
The	  second	  drug	  to	  be	  tested	  was	  tamoxifen	  which	  inhibits	  the	  binding	  of	  estradiol	  to	  
estrogen	  receptors	  hence	  used	  in	  the	  treatment	  of	  hormone-­‐receptor	  positive	  breast	  cancer	  
and	  it	  is	  metabolized	  by	  hFMO3	  to	  tamoxifen	  N-­‐oxide	  [14].	  The	  colorimetric	  competition	  
assay	  was	  carried	  out	  using	  tamoxifen	  dissolved	  in	  ethanol	  and	  investigating	  its	  effect	  on	  
methimazole	  S-­‐oxygenation	  at	  concentrations	  ranging	  from	  0	  to	  100	  µM,	  as	  mentioned	  in	  
the	  Methods	  section.	  Also	  in	  this	  case	  spectrophotometric	  measurements	  were	  converted	  
to	  percentage	  inhibition	  of	  methimazole	  conversion,	  with	  a	  calculated	  maximum	  inhibition	  
of	  ∼55%	  (Figure	  3A),	  slightly	  higher	  than	  those	  obtained	  with	  benzydamine.	  	  
The	  third	  substrate	  of	  hFMO3	  selected	  to	  test	  the	  feasibility	  of	  the	  colorimetric	  inhibition	  
assay	  was	  tozasertib.	  This	  drug	  is	  an	  inhibitor	  of	  Aurora	  A,	  Aurora	  B,	  and	  Aurora	  C	  serine-­‐
threonine	  kinases	  that	  regulate	  mitotic	  events	  [15].	  Aurora	  A	  was	  found	  to	  be	  
overexpressed	  in	  many	  human	  tumors	  including	  breast,	  colorectal,	  and	  ovarian	  cancers	  with	  
Aurora	  B	  also	  overexpressed	  in	  various	  types	  of	  cancer.	  Recently	  our	  group	  has	  
demonstrated	  the	  conversion	  of	  tozasertib	  to	  its	  N-­‐oxide	  using	  purified	  recombinant	  hFMO3	  
enzyme	  [10].	  Different	  concentrations	  of	  this	  drug,	  dissolved	  in	  methanol,	  were	  tested	  in	  
the	  colorimetric	  assay	  and	  the	  inhibition	  data	  obtained	  are	  shown	  in	  Figure	  3B.	  In	  this	  case,	  
the	  highest	  inhibition	  of	  methimazole	  S-­‐oxygenation	  was	  around	  41%,	  the	  lowest	  when	  
compared	  to	  the	  previous	  two	  drugs.	  
	  
3.2.	  Extension	  of	  the	  colorimetric	  assay	  to	  probable	  substrates	  of	  hFMO3	  
The	  colorimetric	  competition	  assay	  was	  proven	  to	  be	  reliable	  when	  testing	  known	  drug	  
substrates	  of	  hFMO3,	  as	  demonstrated	  above.	  We	  therefore	  investigated	  its	  reliability	  with	  
other	  probable	  substrates.	  One	  such	  example	  is	  selegiline,	  a	  selective	  inhibitor	  of	  
monoamine	  oxidase	  B	  (MAO-­‐B)	  and	  currently	  used	  in	  the	  treatment	  of	  Parkinson’s	  Disease	  
[16]	  where	  it	  has	  been	  shown	  to	  provide	  moderate	  symptomatic	  benefit	  to	  patients	  at	  the	  
early	  stages	  of	  the	  latter	  mentioned	  disease.	  Furthermore,	  it	  is	  also	  classified	  as	  a	  doping	  
drug	  by	  WADA	  (World	  Anti-­‐Doping	  Agency)	  since	  it	  acts	  as	  an	  amphetamine-­‐type	  stimulant.	  
Selegiline	  has	  previously	  been	  reported	  to	  be	  a	  substrate	  of	  FMO	  in	  studies	  carried	  out	  in	  
rats	  [17].	  Tsutsuni	  and	  co-­‐workers	  [17]	  calculated	  the	  kinetic	  parameters	  of	  selegiline	  and	  
reported	  a	  Km	  of	  177.5	  ±	  12.3	  µM	  with	  a	  Vmax	  of	  2.3	  ±	  0.4	  nmol/min/mg	  protein.	  In	  order	  to	  
determine	  whether	  selegiline	  is	  also	  a	  substrate	  of	  the	  human	  FMO3,	  it	  was	  tested	  with	  the	  
colorimetric	  competition	  assay.	  The	  results	  demonstrated	  how	  selegiline	  competes	  with	  
methimazole	  for	  hFMO3	  activity,	  but	  the	  maximum	  inhibition	  level	  observed	  was	  only	  21%	  
(Figure	  4A),	  much	  lower	  than	  the	  other	  drugs	  tested.	  In	  order	  to	  identify	  the	  enzymatic	  
product,	  high	  resolution	  mass	  spectrometry	  was	  used	  (Figure	  5).	  	  With	  LC-­‐MS	  analysis	  it	  was	  
possible	  to	  confirm	  that	  the	  product	  of	  the	  enzymatic	  reaction	  was	  indeed	  selegiline	  N-­‐
oxide.	  Selegiline	  precursor	  ion	  has	  a	  m/z	  of	  188.1436	  (MS	  not	  shown)	  whereas	  the	  peak	  
observed	  at	  204.1386	  m/z	  corresponds	  to	  the	  precursor	  ion	  of	  selegiline	  N-­‐oxide	  (Figure	  5,	  
left).	  The	  interpretation	  of	  the	  high	  resolution	  MS	  spectrum	  of	  hFMO3	  metabolite	  is	  
reported	  in	  Figure	  5	  (right).	  The	  fragmentation	  of	  selegiline	  N-­‐oxide	  (Fig.	  5)	  resulted	  in	  three	  
peaks	  at	  199.0852	  m/z,	  91.0537	  m/z	  and	  86.0595	  m/z	  corresponding	  to	  a	  loss	  of	  85.0534	  
m/z,	  113.0849	  m/z	  and	  118.0709	  m/z,	  respectively.	  
In	  order	  to	  better	  understand	  the	  affinity	  of	  hFMO3	  for	  selegiline,	  the	  Michaelis-­‐Menten	  
parameters	  were	  calculated	  by	  measuring	  the	  activity	  of	  hFMO3	  with	  selegiline	  in	  the	  
absence	  of	  a	  competing	  substrate.	  The	  calculated	  kinetic	  parameters,	  Km	  value	  of	  314	  µM	  
with	  a	  kcat	  of	  1.4	  min-­‐1	  (Table	  1),	  are	  consistent	  with	  a	  lower	  competitive	  inhibition	  of	  
methimazole	  turnover,	  given	  the	  low	  affinity	  of	  the	  enzyme	  for	  selegiline	  which	  is	  an	  order	  
of	  magnitude	  lower	  than	  the	  other	  drugs	  tested	  (Table	  1).	  	  	  	  
The	  last	  drug,	  clomiphene,	  is	  a	  well-­‐known	  drug	  used	  for	  the	  treatment	  of	  infertility	  in	  
woman	  [18].	  However,	  it	  is	  also	  classified	  by	  WADA	  as	  a	  doping	  drug	  since	  through	  a	  
complex	  mechanism,	  accelerates	  testosterone	  secretion	  [19].	  The	  drug	  contains	  a	  mixture	  
of	  two	  active	  isomers	  that	  are	  known	  as	  enclomiphene	  and	  zuclomiphene.	  Clomiphene	  has	  
not	  been	  previously	  reported	  as	  a	  substrate	  of	  hFMO3	  but	  was	  selected	  in	  this	  work	  due	  to	  
its	  chemical	  structure	  similarity	  to	  tamoxifen	  (Figure	  3)	  and	  therefore	  its	  ability	  to	  compete	  
with	  methimazole	  binding	  to	  hFMO3,	  was	  tested	  again	  with	  the	  colorimetric	  assay.	  
Surprisingly,	  the	  drug	  competed	  very	  efficiently	  with	  methimazole	  for	  the	  hFMO3	  active	  site	  
and	  was	  already	  able	  to	  inhibit	  methimezole	  conversion	  at	  a	  low	  concentration	  of	  only	  10	  
µM.	  Maximum	  inhibition	  was	  observed	  using	  50	  µM	  clomiphene,	  where	  60%	  inhibition	  was	  
reached	  (Figure	  4B),	  higher	  than	  any	  of	  the	  other	  four	  drugs.	  	  
As	  mentioned	  earlier,	  to	  date	  there	  are	  no	  reports	  of	  clomiphene	  as	  a	  substrate	  of	  hFMO3	  
and	  therefore	  the	  enzymatic	  product	  formed	  was	  identified	  and	  confirmed	  by	  high	  
resolution	  mass	  spectrometry	  as	  the	  N-­‐oxide	  (Figure	  6).	  The	  fragmentation	  of	  clomiphene	  
N-­‐oxide	  precursor	  ion	  (422.1884	  m/z)	  resulted	  in	  five	  peaks,	  with	  the	  main	  one	  at	  313.1228	  
m/z	  (C22H17O2).	  The	  interpretation	  of	  the	  high	  resolution	  MS	  spectrum	  of	  hFMO3	  metabolite	  
is	  also	  reported	  in	  Figure	  6	  (right).	  
Subsequently,	  kinetic	  parameters	  were	  also	  calculated	  for	  clomiphene	  to	  better	  understand	  
both	  substrate	  affinity	  and	  turnover	  rates.	  Results	  obtained	  show	  a	  Km	  value	  of	  18	  µM	  and	  a	  
kcat	  of	  0.1	  min-­‐1,	  demonstrating	  the	  higher	  affinity	  of	  hFMO3	  for	  clomiphene,	  in	  line	  with	  the	  
greater	  level	  of	  inhibition	  observed	  with	  the	  competitive	  assay.	  	  
	  
4.   CONCLUSIONS 
Human	  FMO3	  is	  a	  drug	  metabolising	  enzyme	  but	  within	  the	  last	  few	  years,	  it	  has	  also	  been	  
implicated	  as	  a	  key	  enzyme	  outside	  the	  field	  of	  drug	  metabolism.	  Recent	  reports	  have	  
demonstrated	  how	  FMO3	  is	  involved	  in	  diabetes,	  atherosclerosis	  and	  oxidative	  stress	  [20-­‐
23]	  and	  how	  its	  inhibition	  can	  have	  a	  preventative	  effect	  in	  the	  development	  of	  these	  
disorders.	  These	  studies	  have	  highlighted	  the	  need	  for	  novel	  rapid	  methodologies	  that	  can	  
not	  only	  identify	  potential	  new	  substrates	  of	  hFMO3	  but	  also	  inhibitors	  of	  this	  enzyme.	  The	  
colorimetric	  competitive	  assay	  reported	  here,	  can	  be	  one	  such	  method	  allowing	  for	  the	  
screening	  of	  potential	  substrates/inhibitors	  of	  FMO	  enzymes	  through	  spectrophotometric	  
measurements.	  	  
The	  results	  obtained	  clearly	  demonstrate	  that	  all	  the	  five	  substrates	  tested	  in	  this	  study	  can	  
compete	  with	  methimazole	  for	  binding	  to	  hFMO3.	  The	  already	  known	  substrates,	  
benzydamine,	  tamoxifen	  and	  tozasertib,	  show	  percentage	  inhibition	  values	  between	  40-­‐
55%.	  In	  the	  case	  of	  selegiline,	  this	  inhibition	  value	  was	  decreased	  to	  21%,	  less	  than	  half	  the	  
value	  measured	  for	  the	  other	  drugs	  and	  in	  order	  to	  rationalize	  this	  lower	  value	  the	  kinetic	  
parameters	  of	  selegiline	  metabolism,	  not	  previously	  reported	  for	  the	  human	  enzyme,	  were	  
calculated.	  The	  fact	  that	  a	  high	  Km	  value	  of	  314	  µM	  was	  measured	  is	  in	  line	  with	  the	  low	  
level	  of	  inhibition	  observed.	  The	  exact	  opposite	  was	  observed	  with	  clomiphene,	  with	  a	  17	  
folds	  lower	  Km	  (18	  µM)	  which	  was	  shown	  to	  strongly	  compete	  with	  methimazole	  exhibiting	  
the	  highest	  percentage	  of	  inhibition	  amongst	  the	  drugs	  tested	  i.e.	  60%.	  	  
Finally,	  the	  data	  presented	  demonstrate	  how	  this	  colorimetric	  assay,	  which	  is	  both	  rapid	  and	  
easy	  to	  perform,	  can	  lead	  to	  the	  identification	  of	  new	  substrates	  or	  inhibitors	  of	  hFMO3.	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TABLES	  	  
	  
Table	  1.	  Competitive	  inhibition	  data	  of	  hFMO3	  using	  the	  colorimetric	  assay	  including	  its	  
kinetic	  parameters	  with	  five	  selected	  drugs.	  	  
	   Selegiline	   Tozasertib	   Benzydamine	   Tamoxifen	   Clomiphene	  
%Inhibition	  	   21	   41	   47	   55	   60	  
Km	  (µM)	   314	   23a	   56b	   5c	   18	  
kcat	  (min-­‐1)	   1.4	   9.3a	   9.0b	   16.4c	   0.1	  
	  
a	  ref	  [10]	  
b	  ref	  [9]	  




	   	  
Figure	  legends	  
	  
Figure	  1.	  Scheme	  depicting	  the	  reactions	  involved	  in	  the	  colorimetric	  inhibition	  assay.	  
Human	  FMO3	  converts	  methimazole	  to	  its	  S-­‐oxide	  which	  in	  turn	  oxidizes	  TNB	  (yellow)	  to	  
generate	  DTNB	  (colorless).	  If	  a	  second	  drug	  competes	  with	  methimazole	  for	  binding	  to	  
hFMO3,	  TNB	  oxidation	  is	  inhibited	  and	  therefore	  the	  reaction	  is	  not	  bleached.	  
	  
Figure	  2.	  Competitive	  inhibition	  of	  methimazole	  turnover	  by	  benzydamine.	  Histograms	  
represent	  the	  average	  of	  3	  replicate	  reactions	  of	  inhibition	  obtained	  after	  30	  (blue)	  or	  60	  
(red)	  minutes	  at	  concentration	  of	  0.1,	  0.5	  and	  1	  mM	  benzydamine.	  
	  
Figure	  3.	  The	  colorimetric	  inhibition	  assay.	  Histograms	  represent	  the	  average	  of	  3	  replicate	  
reactions	  of	  inhibition	  obtained	  after	  30	  minutes	  with	  two	  previously	  known	  substrates	  of	  
hFMO3;	  Tamoxifen	  (a)	  and	  Tozasertib	  (b).	  
	  
Figure	  4.	  The	  colorimetric	  inhibition	  assay	  extended	  to	  the	  screening	  of	  two	  new	  drugs	  of	  
hFMO3.	  Histograms	  represent	  the	  average	  of	  3	  replicate	  of	  inhibition	  reactions	  obtained	  
after	  30	  minutes	  with	  two	  previously	  unknown	  substrates	  of	  hFMO3;	  Selegiline	  (a)	  and	  
Clomiphene	  (b).	  
	  
Figure	  5.	  High	  resolution	  MS/MS	  spectra	  of	  Selegiline-­‐N-­‐oxide	  protonated	  ions.	  The	  
corresponding	  fragmentation	  pattern	  of	  these	  molecular	  ions	  is	  reported	  on	  the	  right.	  	  
	  
Figure	  6.	  High	  resolution	  MS/MS	  spectra	  of	  Clomiphene-­‐N-­‐oxide	  protonated	  ions.	  The	  
corresponding	  fragmentation	  pattern	  of	  these	  molecular	  ions	  is	  reported	  on	  the	  right.	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